First-line amivantamab plus platinum-based chemotherapy provided a significantly longer median PFS versus chemotherapy alone (11.4 vs 6.7 months, respectively; HR for disease progression or death, 0.40; 95% CI: 0.30-0.53; P < .001) in patients with advanced/unresectable EGFR Ex20ins-mutated NSCLC in the phase 3 PAPILLON study.32 Here, EGFR is linked to non-small cell lung carcinoma.